HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Freedom Protection Act, take two

This article was originally published in The Tan Sheet

Executive Summary

Ron Paul, R-Texas, and others reintroduced the Health Freedom Protection Act, H.R. 2117, May 1. Paul first introduced the bill in November 2005 (1"The Tan Sheet" Nov. 14, 2005, p. 10). The bill seeks to amend the Food, Drug and Cosmetic Act to allow broader dietary supplement claims, even venturing into the drug arena. The bill also seeks a more rapid response to health claims - after 100 days if there is no response from the HHS secretary the claims would be allowed. The legislation also proposes FTC must notify advertisers before the agency conducts an investigation and give 30 days for companies to discontinue their ads...

You may also be interested in...



Greater Claims Leeway Proposed By Health Freedom Protection Act

A bill introduced in Congress Nov. 9 would "prevent FDA from disallowing structure function claims that include terms that refer to signs or symptoms of disease so long as the disease itself is not mentioned.

Deals In Depth: March 2021

BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.  

The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Topics

UsernamePublicRestriction

Register

RS138343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel